Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 21;11(1):292–305.e2. doi: 10.1016/j.jaip.2022.10.010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

The SARS-CoV-2–specific T-cell responses in 22q11.2DS patients before (6 months after the second dose) and after the third dose of mRNA (BNT162b2) vaccine. The cumulative IFN-γ–positive T-cell responses (total SFC against (A) complete WT Spike, (B) Omicron Spike, and (C) Omicron WT antigens) were evaluated by the T-SPOT Discovery SARS-CoV-2 ELISpot assay in 16 virus-naive participants. Statistical analyses were performed using the Wilcoxon matched-pairs signed-rank test. ∗∗P < .01; ∗∗∗P < .001. SFC, spot forming cells.